Dose escalation pharmacokinetics and lipid lowering activity of a novel farnesoid X receptor modulator: 16-Dehydropregnenolone

Indian Journal of Pharmacology

Volumn 44, Issue 1, 2012, Pages 57-62

  Kumar, Devendra ^a   Khanna, Ashok K ^a   Pratap, Ram ^a   Sexana, Jitendra K ^a   Bhatta, Rabi S ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

80 574; Dose escalation pharmacokinetics; lipid lowering activity

Indexed keywords

16 DEHYDROPREGNENOLONE; 5 PREGNENE 3BETA OL 16,17 EPOXY 20 ONE; FARNESOID X RECEPTOR; PREGNANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HYPERLIPIDEMIA; MALE; NONHUMAN; PHARMACOKINETICS; RAT;

EID: 84856389496     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.91868     Document Type: Article

References (18)

1. Pratap R,Gupta RC, Chander R, Khanna AK, Srivastava AK, Raina D, et al. Method of treating hyperlipidemic and hyperglycemic conditions in mammals using pregnadienols and pregnadienones Patent no 6,875,758, 1999.
2. Pratap R, Gupta RC, Chander R, Khanna AK, Srivastava AK, Raina D, et al. Method of treating hyperlipidemic and hyperglycemic conditions in mammals using pregnadienols and pregnadienones Patent no. 99302556.8, 1999.
3. CDRI Annual Report 2006-07. Lucknow: Central Drug Research Institute; 2007.
4. Wu J, Xia C, Meier J, Li S, Hu X, Lala DS. The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol Endocrinol 2002;16:1590-7. (Pubitemid 34743677)
5. Suryawanshi S, Singh SK, Gupta RC. A sensitive and selective HPLC/ESI-MS/MS assay for the simultaneous quantification of 16- dehydropregnenolone and its major metabolites in rabbit plasma. J Chromatogr B 2006;830:54-63. (Pubitemid 41831388)
6. Sabarinath S, Madhusudanan KP, Gupta RC. Pharmacokinetics of the diastereomers of arteether, a potent antimalarial drug, in rats. Biopharm Drug Dispos 2005;26:211-23. (Pubitemid 41341821)
7. Jia L, Noker PE, Coward L, Gorman GS, Protopopova M, Tomaszewski JE. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol 2006;147:476-85. (Pubitemid 43355045)
8. Tamasi G, Borsy J, Patthy A. Comparison of the antilipemic effect of nicotinic acid (NA) and 3-methylpyrazole-5-carboxylic acid (MPC) in rats. Biochem Pharmacol 1968;17:1789-94.
9. Batra S, Srivastava S, Singh K, Chander R, Khanna AK, Bhaduri AP. Syntheses and biological evaluation of 3-substituted amino-1-aryl-6-hydroxy-hex- 2-ene-1-ones as antioxidant and hypolipidemic agents. Bioorg Med Chem 2000;8:2195-209. (Pubitemid 30612510)
10. Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 1988;16:303-9.
11. Eyal S, Meir B. The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model. Biopharm Drug Dispos 2004;25:157-62.
12. Zuo Z, Kwon G, Stevenson B, Diakur J, Li W. Flutamide-hydroxypropy-beta- cyclodextrin complex: Formulation, physical characterization, and absorption studies using the Caco-2 in vitro model. J Pharm Pharm Sci 2000;3:220-7.
13. Kim JH, Lee SK, Ki MH, Choi WK, Ahn SK, Shin HJ, et al. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin. Int J Pharm 2004;272:79-89.
14. Wang Y, Roy A, Sun L, Lau CE. Short communication: A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab Dispos 1999;27:855-9. (Pubitemid 29347583)
15. Shim CK, Suh MK. Multiple plasma peaks of acetaminophen and ranitidine after simultaneous oral administration to rats. Arch Pharm Res 1992;15:246-50.
16. Brian D, Tim M. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-5.
17. Sargel L. Applied biopharmaceutical and pharmaceutics. 4 th ed. London: Prenitice-Hall International; 1999.
18. Dickinson RG, Harland RC, Ilias AM, Rodgers RM, Kaufman SN, Lynn RK, et al. Disposition of valproic acid in the rat: Dose-dependent metabolism, distribution, enterohepatic recirculation and choleretic effect. J Pharmacol Exp Ther 1979;211:583-95. (Pubitemid 10176078)